Hercules Capital, Inc. is the lender on senior secured term loans that mature in 2031, and most of the money is milestone-based or at the lender's discretion. The filing does not say how the company will use the proceeds.
RA Capital exchanged 4,850,000 shares and Biotechnology Value Fund exchanged 1,750,000 shares. The company had 51,007,874 shares outstanding as of January 23, 2026.
4D Molecular Therapeutics priced an offering of about $100 million in shares and pre-funded warrants at $10.51 each, with Leerink Partners LLC and Evercore Group L.L.C. as joint bookrunners. Preliminary cash of $372.2 million is unaudited, and new buyers face immediate dilution of $1.36 per share.
4D Molecular Therapeutics agreed on October 31, 2025 to license 4D-150 to Otsuka for Asia-Pacific markets in exchange for an $85 million upfront payment. The company keeps leading global Phase 3 work, and Otsuka's expected cost sharing is at least $50 million over three years.
Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $70.4 million, plus short-term investments of $291.0 million, $361.3 million in all.
Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.
Questions about 4D Molecular Therapeutics
Has 4D Molecular Therapeutics raised money recently?
Our latest story on this, dated Nov 6, 2025: "4D Molecular Therapeutics prices $99,999,993 stock offering at $10.5100". The story links the filing or release it is based on. Read the story.
What is the ticker symbol of 4D Molecular Therapeutics?
4D Molecular Therapeutics, Inc. trades under the ticker FDMT on NASDAQ.
Where is 4D Molecular Therapeutics listed?
4D Molecular Therapeutics, Inc. is listed on NASDAQ.
What is the SEC CIK of 4D Molecular Therapeutics?
The SEC Central Index Key (CIK) for 4D Molecular Therapeutics, Inc. is 1650648. Its filings are on SEC EDGAR.
How many shares does 4D Molecular Therapeutics have outstanding?
49,778,127 shares as of 2024-02-23, per the cover page of its 10-K filed 2024-02-29.
Which country or territory is 4D Molecular Therapeutics listed under?
Our directory records 4D Molecular Therapeutics, Inc. under United States.
What does 4D Molecular Therapeutics do?
Our directory classifies 4D Molecular Therapeutics, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
What is the ISIN of 4D Molecular Therapeutics?
The ISIN recorded for 4D Molecular Therapeutics, Inc. is US35104E1001.
Does aibio.space cover 4D Molecular Therapeutics?
aibio.space lists 4D Molecular Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
Where is 4D Molecular Therapeutics incorporated?
SEC records list its state or country of incorporation as DE.
What was 4D Molecular Therapeutics's revenue last year?
$85.2 million for the fiscal year ended Dec 31, 2025, as reported to the SEC.
Is 4D Molecular Therapeutics profitable?
4D Molecular Therapeutics, Inc. reported a net loss of $140.1 million for the fiscal year ended Dec 31, 2025, and used $109.1 million of cash in operations, per its annual report to the SEC.
How much does 4D Molecular Therapeutics spend on research and development?
$195.7 million in the fiscal year ended Dec 31, 2025, per its annual report.
How much cash does 4D Molecular Therapeutics have?
$361.3 million in cash and short-term investments at Jun 30, 2026, per its 10-Q.
What is the latest 4D Molecular Therapeutics (FDMT) stock news?
Our latest story on 4D Molecular Therapeutics, dated Jun 24, 2026: "4D Molecular Therapeutics signs up to $200.0 million Hercules loan". Hercules Capital, Inc. is the lender on senior secured term loans that mature in 2031, and most of the money is milestone-based or at the lender's discretion. The filing does not say how the company will use the proceeds. Source.
Investor discussion: 4D Molecular Therapeutics
Members talk about 4D Molecular Therapeutics (FDMT). Reader posts, not aibio.space reporting, and not investment advice.
Rules
Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
Say whether you hold the stock. Every post states long, short or no position.
No paid or sponsored posts. Do not post for anyone who pays or rewards you.
No buy or sell calls and no price targets.
No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
No personal details and no spam. No links at all for your first 7 days as a member.
Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.
Capital-markets timeline
Financings, listing notices, splits, legal actions and other investor events at 4D Molecular Therapeutics, newest first. Each line links the filing it comes from.
Financings
Reported an unregistered sale of its securities. SEC Form 8-K (Items 3.02,9.01). Source
Financings
Filed a final prospectus for a securities offering. SEC Form 424B5. Source
Financings
Reported an unregistered sale of its securities. SEC Form 8-K (Items 3.02,9.01). Source
Stock chart
Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open NASDAQ:FDMT on TradingView.
SEC filings and registration
SEC name
4D Molecular Therapeutics, Inc.
CIK
1650648
Industry (SIC)
Biological Products, (No Diagnostic Substances) (2836)
US tickers
FDMT (Nasdaq)
State or country of incorporation
DE
Fiscal year ends
December 31
Filer category
Non-accelerated filer<br>Smaller reporting company
Business address
5858 HORTON STREET #455, EMERYVILLE, CA, 94608
Phone
5105052680
Shares outstanding
49,778,127 as of 2024-02-23 (10-K filed 2024-02-29)
Source: SEC EDGAR, retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.
Listing details
4D Molecular Therapeutics, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker FDMT, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.
Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.
Published and maintained by aibio.space. Not investment advice. How we work.
Who manages this pageThis page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio